ZENTALIS PHARMACEUTICALS INC's ticker is ZNTL and the CUSIP is 98943L107. A total of 121 filers reported holding ZENTALIS PHARMACEUTICALS INC in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $60,933 | -71.6% | 14,898 | +9.4% | 0.00% | -100.0% |
Q1 2024 | $214,557 | +2.5% | 13,614 | -1.5% | 0.00% | -50.0% |
Q4 2023 | $209,343 | -25.7% | 13,818 | -1.6% | 0.00% | 0.0% |
Q3 2023 | $281,763 | -14.5% | 14,046 | +20.2% | 0.00% | -33.3% |
Q2 2023 | $329,577 | +44.9% | 11,683 | -11.7% | 0.00% | +50.0% |
Q1 2023 | $227,522 | -12.2% | 13,228 | +2.8% | 0.00% | -33.3% |
Q4 2022 | $259,061 | -3.3% | 12,863 | +3.9% | 0.00% | 0.0% |
Q3 2022 | $268,000 | -22.8% | 12,383 | +0.3% | 0.00% | 0.0% |
Q2 2022 | $347,000 | +22.6% | 12,349 | +101.7% | 0.00% | +50.0% |
Q1 2022 | $283,000 | -44.5% | 6,123 | +1.0% | 0.00% | -50.0% |
Q4 2021 | $510,000 | +36.0% | 6,063 | +7.7% | 0.00% | +33.3% |
Q3 2021 | $375,000 | +27.6% | 5,627 | +1.9% | 0.00% | +50.0% |
Q2 2021 | $294,000 | +27.3% | 5,520 | +3.8% | 0.00% | 0.0% |
Q1 2021 | $231,000 | -14.8% | 5,320 | +1.9% | 0.00% | 0.0% |
Q4 2020 | $271,000 | – | 5,221 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Decheng Capital Management III (Cayman), LLC | 2,099,583 | $42,117,635 | 14.06% |
Mayo Clinic | 187,143 | $3,754,089 | 7.23% |
Matrix Capital Management Company, LP | 13,959,973 | $280,037,058 | 3.36% |
5AM Venture Management, LLC | 490,000 | $9,829,400 | 2.83% |
Eventide Asset Management | 7,814,039 | $156,749,622 | 2.82% |
TYBOURNE CAPITAL MANAGEMENT (HK) LTD | 961,486 | $19,287,410 | 2.70% |
Avidity Partners Management LP | 2,100,000 | $42,126,000 | 1.70% |
First Light Asset Management, LLC | 848,477 | $17,020,449 | 1.62% |
Sofinnova Investments, Inc. | 1,211,641 | $24,305,518 | 1.53% |
SECTORAL ASSET MANAGEMENT INC | 386,525 | $7,753,692 | 1.51% |